"GLP-1s slow your stomach" gets repeated constantly, but rarely with numbers. How slow? Does it last? Is it the same as gastroparesis? And does food really sit there and ferment? The short version: the slowing is smaller than the phrase suggests, it fades with the weekly drugs but doesn't disappear, slowed emptying and gastroparesis are related but different, and no study supports the fermentation claim.
What GLP-1s do to the stomach
GLP-1 is one of the gut's own "stop eating" signals. The medications copy it, and one result is that food leaves the stomach more slowly. The label says so directly. The Wegovy prescribing information states that it "delays gastric emptying" and that this can change how other oral medicines are absorbed (Wegovy prescribing information (external link)).
The slowdown helps explain why you feel full sooner and longer, and it sits behind much of the nausea, bloating, and reflux people report. It's only one of several ways these drugs reduce appetite (see what is suppression, satiation, and satiety on a GLP-1).
How much slower is it, really?
Often less than you'd expect, and it depends on the drug, the dose, and how long you've been on it. Most of the evidence comes from trials that track how fast a marker from a test meal shows up in the blood, not from imaging the stomach (more on that below).
- Semaglutide 1.0 mg, 12 weeks (30 adults with obesity). The first hour after a meal was delayed (marker absorption in that hour was 27% lower), but overall emptying over five hours wasn't statistically different from placebo (Hjerpsted et al., Diabetes, Obesity and Metabolism, 2018, DOI (external link)).
- Semaglutide 2.4 mg, 20 weeks (72 adults with obesity). The trial reported no evidence of delayed gastric emptying at week 20, even though appetite and food intake dropped sharply (Friedrichsen et al., Diabetes, Obesity and Metabolism, 2021, DOI (external link)).
- Oral semaglutide 50 mg, 20 weeks (61 adults with obesity). No statistically significant difference in gastric emptying (Gabe et al., Diabetes, Obesity and Metabolism, 2024, DOI (external link)).
- Tirzepatide. A single dose delayed emptying in people with and without type 2 diabetes. After repeated doses in healthy volunteers the effect shrank. In people with type 2 diabetes on a dose-escalation schedule, a residual delay was still seen (Urva et al., Diabetes, Obesity and Metabolism, 2020, DOI (external link)). The manufacturer ran that study, and it included mouse experiments.
Two cautions go with these numbers. The studies are small and short, and most were sponsored by the drug makers. And the "no delay" findings rely on an indirect method with real blind spots, covered in the measurement section.
Does it stay slow, or return to normal?
Partly. Researchers call this tachyphylaxis: the body adapts to a steady drug signal and responds less to it over time.
- A review by an Adelaide research group that has studied this for years describes the pattern for long-acting drugs. With liraglutide, the stomach's half-emptying time was clearly longer after about five weeks but significantly less so after 16 weeks. Shorter-acting drugs, which peak and trough, show little of this fading (Jalleh et al., Journal of Clinical Endocrinology & Metabolism, 2024, DOI (external link)).
- The same review says some "residual slowing" remains with long-acting agents, so the effect shrinks without vanishing.
- Anesthesiologists reviewing the evidence concluded that ongoing treatment attenuates the effect, and that after more than 12 weeks, standard fasting times likely suffice for most otherwise low-risk patients. That is an expert editorial view, not a trial result, and not advice for any individual (van Zuylen et al., British Journal of Anaesthesia, 2024, DOI (external link)).
In practice, the stomach effect is strongest in the first weeks and after dose increases, which is also when many people have their worst nausea. The multisociety perioperative guidance makes the same point, saying the escalation phase carries a higher risk of delayed emptying than the maintenance phase (Kindel et al., Clinical Gastroenterology and Hepatology, 2024, DOI (external link)). See how GLP-1 titration schedules work and managing nausea on a GLP-1. Appetite effects can also continue after the stomach effect has faded, since slowed emptying is only one of the ways these drugs work.
How gastric emptying is measured
There's no home test. The options are:
- Scintigraphy (the reference standard). You eat a standardized low-fat egg-white meal labeled with a tiny amount of radioactive tracer, and a camera tracks how much is left in your stomach at 0, 1, 2, and 4 hours. A joint consensus from the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine recommends this protocol so results are comparable between centers (Abell et al., American Journal of Gastroenterology, 2008, DOI (external link)). Studies that apply it have typically called emptying delayed when more than 10% of the meal remains at 4 hours (Samosir et al., Acta Medica Indonesiana, 2011, PubMed (external link)). It costs more, takes hours, involves radiation exposure, and isn't available everywhere. Many centers also depart from the standard meal, which can change the answer (Freiberg, Journal of Nuclear Medicine Technology, 2025, DOI (external link)).
- Stable-isotope breath test. A noninvasive alternative: you eat a meal containing a labeled ingredient and breathe into collection tubes (per the Jalleh review above).
- Paracetamol (acetaminophen) absorption. Most GLP-1 trials use this. The drug is absorbed after the stomach empties, so its blood level rises faster when emptying is faster. It tracks liquids well but can't reliably measure how solids empty, and solids are the part most likely to be held up (Jalleh et al., as above).
- Point-of-care gastric ultrasound. Used right before sedation or surgery to see whether the stomach still holds food or fluid.
This matters when you read the research. A trial that shows "no change" on a paracetamol test has shown no change in how liquids empty. It hasn't shown that a solid meal moves normally.
How this relates to gastroparesis
Slowed emptying is an expected effect of the drug. Gastroparesis is a diagnosis. It means the stomach empties abnormally slowly with no blockage, along with persistent symptoms: nausea, vomiting, early fullness, bloating, upper abdominal pain. A GLP-1 can cause mild, temporary slowing without anyone having gastroparesis. The label does warn that the drug is "not recommended in patients with severe gastroparesis" (Wegovy prescribing information (external link)).
What the evidence shows:
- Does a GLP-1 cause gastroparesis? There's a signal, but the numbers are small and the certainty is low. In a claims-database analysis, gastroparesis was diagnosed at about 9.1 per 1,000 person-years on semaglutide, 7.3 on liraglutide, and 3.1 on bupropion-naltrexone. The adjusted hazard ratio for GLP-1 agonists versus bupropion-naltrexone was 3.67, but with a very wide confidence interval (1.15 to 11.90) from a few thousand users, and the authors noted they couldn't confirm every user was taking the drug for weight loss (Sodhi et al., JAMA, 2023, DOI (external link)). A large later cohort of people with type 2 diabetes found similar rates of a composite of serious GI outcomes (which included gastroparesis) across dulaglutide, semaglutide, and tirzepatide. That shows the drugs resemble each other, but not whether they differ from no treatment (Crisafulli et al., Annals of Internal Medicine, 2025, DOI (external link)).
- If your stomach is already slow. The Jalleh review reports that GLP-1 drugs add little further slowing in people whose emptying is already abnormally delayed at baseline. That doesn't make them safe for this group. The physiology differs, and we found no good outcome data for people with diagnosed gastroparesis.
- If you have diagnosed gastroparesis, or symptoms that sound like it, raise it with your prescriber before starting, and again for anything persistent or severe once you're on treatment. See talking to your doctor about side effects that aren't improving.
Why it matters before a procedure
The one place slowed emptying has a clear, documented consequence is a procedure that needs an empty stomach. Two large meta-analyses of upper endoscopy found GLP-1 users had about 4.5 to 5 times the odds of food still in the stomach (odds ratio 4.54 across 262,018 patients, and 4.86 across 1,253,498 subjects), and more interrupted or repeated procedures (Baig et al., Gastrointestinal Endoscopy, 2025, DOI (external link); Tan et al., Digestive and Liver Disease, 2025, DOI (external link)).
The two analyses disagree on the most serious outcome. One found no significant difference in aspiration pneumonia (odds ratio 0.96); the other found a higher risk of pulmonary aspiration (odds ratio 2.29). Aspiration events are rare, the underlying studies are observational, and the pooled results differ, so no one can give you a confident single number. The label now includes a warning about rare postmarketing aspiration reports in people who had residual stomach contents despite following fasting instructions (Wegovy prescribing information (external link)).
A multisociety guidance document from 2024, endorsed by the American Gastroenterological Association, American Society of Anesthesiologists, American Society for Metabolic and Bariatric Surgery, International Society of Perioperative Care of Patients with Obesity, and Society of American Gastrointestinal and Endoscopic Surgeons, takes a case-by-case approach. It says GLP-1 use around a procedure should rest on shared decision-making between the patient and the procedural, anesthesia, and prescribing teams. It lists higher doses, weekly formulations, the escalation phase, and current GI symptoms (nausea, vomiting, abdominal pain, dyspepsia, constipation) as factors that raise risk. For higher-risk patients it suggests a liquid diet for at least 24 hours beforehand, and if holding the drug is decided, holding for a week before surgery for weekly formulations and the day of surgery for daily ones. The authors describe it as guidance, not an evidence-based guideline (Kindel et al., Clinical Gastroenterology and Hepatology, 2024, DOI (external link)).
Follow the instructions from the team doing your procedure, and tell them you take a GLP-1. Don't stop the drug, continue it, or change your fasting on your own based on what you read here.
The myth: "slow emptying makes food ferment and rot in your stomach"
Verdict: no evidence supports this as stated.
The kernel of truth. Food does sit in the stomach longer when it's slowed, and many people feel that. Bloating, burping, and a heavy, stuck feeling are real. Fermentation is what produces gas in the gut, so it's natural to link the two.
The best case for the claim. If food stays warm and moist for longer, it seems reasonable that bacteria would have more time to work on it.
Why it doesn't hold up.
- We found no study that tested it. Our searches of the medical literature turned up no research showing fermentation or bacterial growth in the stomach of GLP-1 users. Absence of evidence isn't proof, but it means the claim is circulating without a source.
- The stomach is an acid environment. Stomach acid normally kills many microbes that arrive with food, and when acid secretion drops, microbes that would normally be killed can survive and grow (Dicksved et al., Journal of Medical Microbiology, 2009, DOI (external link)). That study looked at people with reduced acid, not GLP-1 users, so it supports the general principle and nothing more. We found nothing showing that GLP-1s shut off stomach acid.
- The delay is hours, not days. GLP-1s slow emptying without stopping it, and the trials above show the average slowing is modest and fades.
- The symptoms have simpler explanations. Bloating and burping on a GLP-1 fit slowed emptying itself, swallowed air, and meals bigger than the stomach now tolerates. No bacteria are needed to explain them.
Something real exists further down the gut. The bacteria that can overgrow in a slowed gut live in the small intestine, not the stomach. This is small intestinal bacterial overgrowth, or SIBO. In a retrospective analysis of medical records from people with type 2 diabetes, confirmed SIBO was diagnosed more often in people starting GLP-1 or GLP-1/GIP drugs than in people starting other diabetes drugs: 0.177 versus 0.083 per 1,000 patient-years in the first year (hazard ratio 2.14, 95% CI 1.13 to 4.07). Over up to five years the difference wasn't statistically significant (hazard ratio 2.02, 95% CI 0.98 to 4.12) (Sun et al., Diagnostics, 2025, DOI (external link)). The absolute numbers are very small, the study is retrospective and can't prove cause, and it counts diagnosed cases, so it says nothing about how common milder problems are. The authors suggest testing only when symptoms point to it.
How to talk about it. "Food isn't rotting in your stomach. The stomach is acidic and the delay is temporary. Gas and bloating on a GLP-1 usually come from slowed movement and meal size. A rare small-bowel bacterial overgrowth is possible, and worth raising with your prescriber if you have persistent bloating, gas, or diarrhea."
What to actually do about the symptoms
- Eat smaller portions, more slowly, and stop at comfortable. A slowed stomach has less room for a big meal.
- Go easy on very fatty or greasy foods if they bother you, without treating any food as forbidden (see myth: you must avoid certain foods on a GLP-1).
- Expect it to be worst after a dose increase and to ease over weeks.
- Constipation and slowed emptying can occur together, and constipation has its own fixes (constipation on a GLP-1). For the wider picture, see common GLP-1 side effects and how to manage them.
- Call your prescriber promptly for vomiting you can't stop, severe or worsening belly pain, a swollen abdomen, or being unable to keep fluids down. That isn't normal slowing. Ileus (a stalled bowel), intestinal obstruction, and pancreatitis all appear in the prescribing information.
What we don't know
- How much GLP-1s slow solid-meal emptying over months in people taking them for weight loss, measured by the reference method. Most long-term data use the paracetamol test.
- Whether the residual slowing that remains after tachyphylaxis is large enough to matter for aspiration risk, and what fasting plan works best. The published guidance is expert consensus, not trial evidence.
- Whether GLP-1s truly cause gastroparesis or bring out a tendency that was already there, and how often. The best available estimate rests on small numbers.
- How common SIBO is in people on GLP-1s outside a diabetes population, and whether the drug causes it.
This is general education, not medical advice. If you have diabetes-related stomach problems, a history of gastroparesis, bowel obstruction or major abdominal surgery, or an upcoming endoscopy or surgery, talk with your prescriber or the procedure team about your situation. Study findings above are attributed to their authors and were located through PubMed.